Identification and use of high efficacy vaccine antigens which modulate antigen presenting cells
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsPOLLY MATZINGER, JOHN PAUL RIDGE
Life of this patent
Estimating the term…
Abstract
The present invention relates to the identification and use of high efficacy vaccine antigens which modulate antigen presenting cells.
Claims48
A method of making a component of a pharmaceutical comprising:
- providing an APC;
- providing a ligand which interacts with the APC;
- contacting the APC with the ligand;
- analyzing the activation state of the APC;
- and
- selecting the ligand as the component of a pharmaceutical wherein the ligand superactivates the APC, as determined by the capacity to activate a killer T cell in the absence of a helper T cell.
A method of making a component of a pharmaceutical comprising:
- providing an APC;
- providing a ligand which interacts with the APC;
- contacting the APC with the ligand;
- analyzing the activation state of the APC;
- and
- selecting the ligand as the component of a pharmaceutical wherein the ligand inhibits superacetivating the APC, as determined by the capacity to block activating a killer T cell in the absence of a helper T cell.
The method of claim 7, wherein the ligand is an antibody selected from the group consisting of 17A10, 2D10, CTLA-4-Ig, and MR1.
A method of making a cancer vaccine component comprising:
- (a) providing an antigen presenting cell (APC) having a tumor antigen;
- (b) providing a ligand which interacts with the APC;
- (c) contacting the APC with the ligand;
- (d) analyzing the activation state of the APC;
- and
- (e) selecting the ligand as the cancer vaccine component wherein the ligand superactivates the APC, as determined by the capacity to activate a killer T cell in the absence of a helper T cell.
A method of making an anti-pathogen vaccine component comprising:
- (a) providing an antigen presenting cell (APC);
- (b) providing a ligand which interacts with the APC;
- (c) contacting the APC with the ligand;
- (d) analyzing the activation state of the APC;
- and
- (e) selecting the ligand as the anti-pathogen vaccine component wherein the ligand superactivates the APC, as determined by the capacity to activate a killer T cell in the absence of a helper T cell.
A method of making a component for immunosupression comprising:
- (a) providing an antigen presenting cell (APC);
- (b) providing a ligand which interacts with the APC;
- (c) contacting the APC with the ligand;
- (d) analyzing the activation state of the APC;
- and
- (e) selecting the ligand as the component for immunosupression, wherein the ligand inhibits superactivating the APC, as determined by the capacity to block activating a killer T cell in the absence of a helper T cell.
A method of activating a killer T cell comprising:
- providing an APC;
- providing a ligand which interacts with the APC;
- contacting the ligand with the APC,
- analyzing the activation state of the APC;
- selecting a superactivated APC;
- and
- contacting the superactivated APC with a killer T cell in the absence of a helper T cell resulting in activation of the killer T cell.
A method of identifying immune responsiveness of a subject comprising:
- (a) providing an APC from the subject;
- (b) providing a ligand which interacts with the APC;
- (c) contacting the APC with the ligand;
- (d) analyzing the activation state of the APC;
- and
- (e) measuring immune responsiveness, wherein the presence of superactivation indicates a good immune responsiveness and wherein the absence of superactivation indicates a poor immune responsiveness.
A kit to identify immune responsiveness comprising:
- an APC;
- a ligand which interacts with the APC;
- a means for contacting the APC with the ligand;
- a means for analyzing the activation state of the APC;
- and
- a means for measuring immune responsiveness, wherein the presence of superactivation indicates a good immune responsiveness and wherein the absecnce of superactivation indicates a poor immune responsiveness.
A method of treating or preventing cancer in a subject comprising:
- removing an APC from a subject in need of a superactivated APC;
- contacting the APC with a cancer cell antigen so as to form an antigen-APC complex;
- contacting the antigen-APC complex with a ligand, wherein the ligand superactivates the antigen-APC complex so as to form a superactivated antigen-APC complex;
- and
- administering to the subject a therapeutically effective amount of the superactivated antigen-APC complex.
A method of treating or preventing infection by a pathogen in a subject comprising:
- removing an APC from a subject in need of a superactivated APC;
- contacting the APC with an antigen from the pathogen so as to form an antigen-APC complex;
- contacting the antigen-APC complex with a ligand, wherein the ligand superactivates the antigen-APC complex so as to form a superactivated antigen-APC complex;
- and
- administering to the subject a therapeutically effective amount of the superactivated antigen-APC complex.
An isolated biological complex comprising a superactivated antigen presenting cell (APC) attached to a killer T cell and not attached to a helper T cell.
Dependencies are inferred from the claim text.